CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. CD19/CD20 Bi-Specific CAR-T ...
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide Seven days before the first ...
Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have been ...
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients. Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) lived twice as long when treated with ...
Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the function of ...
The apoptotic pathway activated by chimeric anti-CD20 monoclonal antibodies (rituximab, IDEC.C2B8) was analyzed using the Burkitt lymphoma cell line Ramos. Crosslinking of CD20 (CD20XL) induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results